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Objective. To evaluate the usefulness of one of IGRAs, QuantiFERON-TB Gold (QFT-G), in human immunodeﬁciency virus-
(HIV- ) infected patients with various CD4+ T cell counts. Methods. The QFT-G assay was performed using QFT-G kits among
107 HIV-infected patients including 9 cases with active tuberculosis (TB). Results. In HIV-infected patients with CD4+ > 50/μL,
QFT-GpositiverateforactiveTBpatientswas5/6(sensitivity= 83%),andthatforthosewithoutactivediseasewas1/69(speciﬁcity
= 99%). The frequency of indeterminate QFT-G test was signiﬁcantly higher in those with CD4+ less than 50/μL( P<. 0001). At
the same time there was a proportional relationship between CD4+ and interferon-gamma response to mitogen (positive control)
in QFT-G test (P = .0001). Conclusions. Our data suggested that QFT-G had high sensitivity and speciﬁcity in HIV-infected
populations with CD4+ greater than 50/μL. However, QFT-G did not perform well in HIV-positive patients with CD4+ less than
50/μL.
1.Introduction
Human immunodeﬁciency virus (HIV) infection is one of
the greatest risks for developing active tuberculosis (TB)
if HIV-infected individuals are or have been infected with
M. tuberculosis (MTB). The risk for developing TB in HIV
coinfected persons increases approximately 20-to 200-fold
compared with immunocompetent individuals [1]. There-
fore, chemotherapy for HIV-infected persons with latent TB
infection (LTBI) is recommended [1]. Although prevalence
of HIV infection in Japan is low (<0.1), the number of HIV-
infected persons is increasing year by year [2].
In the USA, prophylactic treatment for LTBI has been
strongly recommended for HIV-infected persons who have
an induration of 5mm or greater in the tuberculin skin
test (TST) [3]. Although the TST has been provisionally
proposed as a test for TB infection in HIV-infected subjects
in Japan [4], the validity of the TST in this population has
not been suﬃciently evaluated. This is especially the case in
Japan where TST performance is compromised by the past
vaccination with Bacillus Calmette-Guerin (BCG) [5], which
has been widely used in Japan.
In 2005, a new diagnostic test for MTB infection,
QuantiFERON-TB Gold (QFT-G), was approved in Japan.
QFT-G measures T cell responses to Mycobacterium RD1-
speciﬁc antigens, which are absent from BCG vaccine
strains and most nontuberculous mycobacteria (NTM) and
thereby is more speciﬁc than TST [6]. However, as QFT-G
measuresinterferon-(IFN-)gammaproductionfromTcells
responding to the Mycobacterium RD1-speciﬁc antigens, it
is likely that the responses in HIV-infected individuals with
lower T cell number would decline. In acknowledgement
of this, both the US Centers for Disease Control and
Prevention (CDC) and the Japanese Society for Tuberculosis
state in their guidelines the necessity for further research
on the use of QFT-G in immunocompromised populations,2 Clinical and Developmental Immunology
including HIV infected [7, 8]. The CDC guidelines for
opportunistic infections in HIV infected persons, issued in
April 2009, state that IFN-gamma release assays (IGRAs)
such as QFT-G can be used for the diagnosis of LTBI in
this population [9]. Although several reports indicate that
QFT-G had better performance in diagnosing TB infection
in HIV-infected individuals than the TST, sensitivity and
speciﬁcity vary depending on the setting [10, 11]. In Japan,
the only published study of QFT-G in HIV-infected reported
a moderate sensitivity of 67% (6/9) in AIDS-TB comorbidity
patients; however the size of the study was insuﬃcient to
address the general applicability of QFT-G in HIV-infected
individuals [12].
In the present study, we have examined the usefulness
of QFT-G to diagnose MTB infection in HIV-infected
individuals as well as comparing the test performance with
that of the TST.
2.MaterialsandMethods
2.1. Subjects. Inpatients and outpatients of two public gen-
eralhospitals(TokyoMetropolitanFuchuHospital,currently
Tama Medical Center and Komagome Hospital) who were
infected with HIV were enrolled into the study regardless
of antiretroviral therapy (ART) status. HIV-TB comorbidity
was deﬁned as HIV-infected patients with active TB disease.
The active TB diagnosis was conﬁrmed by culture positivity
in 6 cases. Two other cases were clinically diagnosed based
on radiological ﬁndings compatible with active TB and
their response to antituberculosis treatment. Still another
case with tuberculous meningitis was diagnosed so by the
elevation of adenosine deaminase in cerebrospinal ﬂuid.
QFT-G tests were performed together with CD4+ Tc e l l
count. The clinical history and the demographic data were
obtainedfromthemedicalchart.Whenpossible,theTSTwas
also performed. Healthy subjects who were known to be not
infected with HIV and to have no history of active TB nor
MTB exposure were also enrolled as controls.
This study was approved by the ethics committees of the
two hospitals, and informed consent was obtained from all
subjects.
2.2. Tuberculin Skin Test (TST). For patients who could
revisit their hospital 48 hours after placement for test
reading, the TST was performed using the deﬁned standard
test dose of tuberculin PPD in Japan (Nippon BCG Man-
ufacturing Co. Ltd, Tokyo, Japan), which is equivalent to
2.5 TU of PPD-S [13], injected intradermally into the volar
aspect of the forearm. Transverse induration and erythema
diameters were measured 48 to 72 hours later and recorded
by trained healthcare workers. Individuals performing and
reading the TST were blinded to the QFT-G test results.
Induration of 5mm or greater was interpreted as positive,
following the cutoﬀ recommended by the CDC for HIV-
positive individuals.
2.3. QuantiFERON-TB Gold (QFT). The QFT-G assay was
performed using QFT-G kits (Cellestis Limited, Carnegie,
Australia) according to the manufacturer’s instructions. All
blood samples were stimulated with Mycobacterium-speciﬁc
antigens within 8 hours of collection. For those subjects
who were tested also with the TST, blood collection was
done prior to or simultaneously with the QFT-G test. QFT-
G results were interpreted according to CDC guidelines [8].
IFN-gamma responses to either ESAT-6 and/or CFP-10 that
were greater than or equal to 0.35IU/mL above the value for
the respective Nil control were interpreted as positive. If a
person’sresponse(correctedfortheNilcontrol)waslessthan
0.35IU/mL for both TB-speciﬁc antigens and their response
to the mitogen-positive control was above 0.5IU/mL, they
were considered test negative. If the Nil-corrected IFN-
gamma response for an individual was less than 0.35IU/mL
for the antigens and less than 0.5IU/mL for the mitogen-
positivecontrol,anindeterminateresultwasrecorded.Asper
the Japanese interpretation criteria of QFT, a further possible
result for QFT-G, “doubtful positive”, was recorded if the
subject’s response to ESAT-6 and/or CFP-10 was between
0.1 and 0.35IU/mL and the mitogen response greater than
0.5IU/mL [14].
2.4. Data Analysis. The relationship between the QFT-G
results or TST results in association with CD4+ Tc e l l
count in each patient was analyzed. CD4+ Tc e l lc o u n tw a s
classiﬁed in four categories: less than 50/μL ,b e t w e e n5 0a n d
199/μL, between 200 and 499/μL, and 500/μLa n dm o r e .
QFT-G results were entered into Excel 2003 (Microsoft,
Redmond, WA) and transferred to SPSS version 11.0J (SPSS,
Inc. Chicago, IL) for statistical analysis. Chi-squared test
or Fisher’s exact test was used to test the comparison of
proportions, and Kruskal-Wallis test was used for testing
correlation between IFN-γ response to the mitogen and the
CD4+ T cell count level.
3. Results
3.1. Characteristics of Patients. A total of 107 cases including
103 Japanese and 4 Thai were enrolled during the study
period (Table 1). The majority of the patients were males
(92.5%), with a mean age of 46 years (range: 23–75),
and mean±standard deviation of CD4+ Tc e l lc o u n tw a s
215±217/μL (range: 4–934). Fifty-one patients were treated
with ART, of whom only one patient had the CD4+ Tc e l l
count below 50. Ninety-eight subjects did not have active TB
disease while 2 of these had chest X-ray ﬁnding compatible
w i t ho l dT B ,a n do n es u b j e c th a dM. kansasii disease. There
were 9 subjects with active TB, including one newly infected
case who had recent contact with an infectious patient.
CD4+ T cell counts were distributed as shown in Table 1
in patients with or without active TB. The mean cell count
tended to be lower for those with TB than those without TB.
There were 29 healthcare workers (male: 13.8%) with a
mean age of 42 years (range: 23–67), recruited as control
subjects into the study, and the QFT-G assay was performed
for all. They were all negative in the QFT-G assay.
3.2. TST in HIV-Infected Patients. Because many of the
subjects enrolled into the study were outpatients, they couldClinical and Developmental Immunology 3
Table 1: Characteristics of subjects.
Cases with active TB Cases without active TB Total
Nationality (Japanese/Thai) 8/1 95/3 103/4
Gender (Male/Female) 8/1 91/7 99/8
Mean age (range) 53 (39–65) 45 (23–75) 46 (23–75)
Mean and SD of CD4+ T cell count (range)/μL 105 ±90 (9–270) 226 ±221 (4–934) 214 ±215 (4–934)
No. of patients treated with ART 4 44 48 (one interrupted)
TB already treated 0 2 2
Healed TB on chest X-ray 0 2 2
M. kansasii disease 0 1 1
N 9 98 107
not return after 48 hours to have their TST read. Thus,
the TST was placed for only 26 (24%) and the ﬁnal results
obtained for 23 (21.5%). All subjects with a TST result were
Japanese and had been vaccinated with BCG. Of them, 6
had active TB. The TST was positive in 7/23 (30%) patients
and negative in 16/23 (70%) (Table 2). The TST positive rate
was 4/12 (33%) for those with CD4+ Tc e l lc o u n t<200/μL,
compared with 3/11 (27%) for those with CD4+ Tc e l lc o u n t
more than 200/μL( d i ﬀerence nonsigniﬁcant, P for Fisher’s
exact test=1.00).
Six of the 9 HIV-infected patients with active TB had a
TST result, and 3 (50%) were positive. One of these TST
positive patients had CD4+ T cell count less than 50/μL. Of
the 17 subjects without TB and with a TST result, 4 were
positive, equating to a speciﬁcity of 76% (=13/17).
3.3. Relationship between CD4+ T Cell Count, Presence of
Active TB, and QFT-G Results. QFT-G results were available
for all of the 107 HIV-infected subjects, and of them 6 (6%)
were positive, 92 (86%) negative, and 9 (8%) indeterminate
(Table 3). Indeterminate results were signiﬁcantly associated
with very low CD4+T cell count, with frequency of indeter-
minate tests being 25% (8/32) in those with CD4+ Tc e l l
count less than 50/μL, compared with 1% (1/75) in those
with CD4+ T cell count greater than 50/μL (Fisher’s P<
.0001).
For the 9 patients with active TB, 5 (56%) were positive
by QFT-G and 1 (11%) indeterminate. There were 3 TB
patients with CD4+ T cell count less than 50/μL, and QFT-
G was negative for two and indeterminate for the other. In
contrast, all 5 HIV-TB patients with a CD4+ Tc e l lc o u n t
between 50/μL and 199/μL were QFT-G positive, and the
one patient with a CD4+ T cell count between 200/μLa n d
499/μL was negative but the response value was near the
cutoﬀ.Ofthe98HIVpositivesubjectswithoutactiveTB,one
was positive by QFT-G.
If limiting analysis to those HIV patients with a CD4+ T
cell count more than 50/μL, the sensitivity of QFT-G for TB
infection as seen in TB patients as surrogates of the infected
was 83% (5/6), and speciﬁcity was 99% (68/69). QFT-G
was negative in the two subjects with chest X-ray evidence
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Figure 1: Box plot of the interferon-gamma response to mitogen
according to the CD4+ T cell count level. ∗ indicates an outlier.
As for ART status, QFT-G was positive in 3 of 5 active
TB patients with ART and 2 of 4 cases without ART. In one
patient who developed TB within one month after starting
ART, QFT-G was positive.
3.4. Relationship between CD4+ TC e l lC o u n ta n dP o s i t i v e
Control Level in QFT-G. As the QFT-G indeterminate rate
was high for HIV patients with CD4+ T cell count less than
50/μL as seen above, we analyzed the relationship between
CD4+ T cell count and level of responses to the test’s positive
control (stimulation with mitogen) for a total of 95 patients
excluding those with TB (n = 9) or M. kansasii disease
(n = 1) and those with negative control response being
higher than positive control response (n = 2). As shown
in Figure 1 and Table 4, there is a continuous rise in the
response level along with the cell count from less than 50/μL
uptoover500/μLwithstatisticalsigniﬁcance(Kruskal-Wallis
test, P = .0001). There is no signiﬁcant diﬀerence in the
level of response between HIV-infected patients with CD4+4 Clinical and Developmental Immunology
Table 2: Relationship between TST results and CD4+ T cell count.
CD4+ T cell count/μL Presence of active TB disease
∗ TST positive TST negative
<200 [<50] Y( n = 6) 3 (50%) [1]
∗ 3 (50%) [2]
∗
N( n = 6) 1 (17%) [0]
∗ 5 (83%)[3]
∗
≥200 Y( n = 0) 0 0
N( n = 11) 3 (27%) 8 (73%)
Y: present, N: absent.
(%): percentage of Y or N number in each CD4 category.
∗[ ] indicates the number of those with CD4+ T cells less than 50.
Table 3: Relationship between QFT-G results and CD4+ T cell count.
Category by CD4+ T cell count/μLA c t i v e T B Results of QFT-G
Negative Doubtful positive Positive Indeterminate
+
<50 (n = 32) Y( n = 3) 2 (67%) 0 0 1 (33%)
N( n = 29) 22 (76%) 0 0 7 (24%)
50–199 (n = 29) Y( n = 5) 0 0 5 (100%) 0
N( n = 24) 23 (96%) 0 1 (4%) a 0
200–499 (n = 35) Y( n = 1) 0 1 (10%) 0 0
N( n = 34) 32 (94%) 1 (3%) 0 1 (3%)
≥500 (n = 11) N (n = 11) 11(100%) 0 0 0
Total Y( n = 9) 2 (22%) 1 (11%) 5 (56%) 1 (11%)
N( n = 98) 88 (90%) 1 (1%) 1 (1%) 8 (8%)
Y: present, N: absent, and a: M. kansasii disease.
(%): percentage of Y or N number in each CD4 category.
+Indeterminate results were signiﬁcantly associated with CD4+T cell count less than 50/μL, compared with CD4+ T cell count greater than 50/μL( F i s h e r ’ s
P< . 0001).
T cell count greater than 500/μL and healthy control subjects
(Table 4).
4. Discussion
Although the TST has been used as a diagnostic tool for
TB infection for many decades, the speciﬁcity of the TST
is known to be low in not only HIV-infected individuals
but also in the general population of Japan where BCG
vaccination is widely carried out. Moreover, TST requires
two visits of health care providers for administration and
measurement of a test with 48-hour time interval. This is a
signiﬁcant barrier for the cooperation of the patients. In fact,
only 21.5% of the enrolled patients in our study underwent
a TST in the clinical setting of this study, and the number of
cases with TST was not enough for thorough evaluation of
TST results.
The QFT-G was approved in 2005 in Japan, but there
remain several issues to be addressed, such as applicability
of QFT-G for children or for immunocompromised popula-
tions such as HIV infected individuals [15]. Several reports
have been published on QFT-G’s performance in the HIV
infected [10–12], but the present study is the ﬁrst report
whichevaluatestheQFT-Gperformanceinalargenumberof
HIV-infected individuals in Japan, one of TB middle-burden
countries. The data suggest that QFT-G has high sensitivity
for TB infection in HIV coinfected patients who have CD4+
Tc e l lc o u n t> 50/μL, but based on a very small sample size of
active TB cases, the test had poor sensitivity in patients with
very low CD4+ Tc e l lc o u n t( <50/μL).
As would be expected for QFT-G, the test was highly
speciﬁc in the HIV cohort without active TB, with only one
of the 69 non-TB patients being QFT-G positive. The one
person who was QFT-G positive had M. kansasii infection.
This is an expected result as M. kansasii is one of the few
NTMthatcarrytheRD1genewhichencodestheESAT-6and
CFP-10 proteins used in QFT-G [16]. In contrast, the TST
had a poor speciﬁcity of 76% (13/17) in the HIV-positive
subjects tested, likely due to the eﬀects of BCG vaccination
and revaccination in the Japanese population.
Previous studies of QFT-G indeterminate rates for HIV
infected reported that their frequency increased with CD4+
T cell count less than 100 or 200/μL[ 17–20]. Similarly, we
found a signiﬁcant evidence for an increased indeterminate
rate in the group of patients with CD4+ T cell count less
than 50/μL, although the number of each group was not
so large. At the same time we found that there is a clear
proportional relationship between T cell count and the
level of IFN-gamma response in those with cell count less
than 500/μL. This implies that HIV-infected patients with
T cell count above 50/μL (and less than 500/μL) have also
impaired IFN-gamma response more or less although their
QFT-G test results are not “indeterminate”. The diﬀerences
between studies could be due to the relatively small sample
sizes, so that cases with slight decrease of response in those
with intermediate cell count group could be not judged asClinical and Developmental Immunology 5
Table 4: Interferon-gamma responses for mitogen according to CD4+ T cell count category in HIV-infected patients without active TB
disease and healthy controls.
<49/μL 50–199/μL 200–499/μL >500/μL Healthy controls
Number 27 a 22 35 11 29
Mean 7.48 13.50 16.08 20.40 19.27
S.D. 7.03 5.60 5.17 3.20 5.06
Median 5.55 15.51 16.91 20.21 20.03
Maximum 22.93 20.51 23.19 25.18 26.31
Minimum 0.14 0.67 0.25 15.56 5.12
S.D.: standard deviation.
a. 2 of 29 cases were omitted because negative control value was higher than response to mitogen.
“indeterminate” by chance in a small size of observations.
Therefore, care should be taken when we interpret the
negative QFT-G test results of such subjects, as is the case
with the TST. Of course, in such severely immunosuppressed
individuals as with CD4+ T cell count less than 50/μL,
no immunologically based test should be considered as
deﬁnitive and reliable, and clinicians should use all available
information in evaluating MTB infection status.
Comparison of the performance of QFT-G and TST in
diagnosing MTB infection in HIV positive patients was very
limited in our study by the small number of patients for
whom TST results were available. QFT-G appeared to have
at least as good sensitivity as the TST and signiﬁcantly better
speciﬁcity, but the number of subjects was insuﬃcient to
make deﬁnitive conclusions. Of interest was the very low
number of subjects for whom TST results were available
(23/107). For most people who were not tested by TST, this
was due to the requirement to return 48 hours later to have
the test read. This highlights a signiﬁcant beneﬁt of QFT-
G—the fact that only one visit to the clinician is required to
obtain a result.
There were some limitations in our study. We used
the liquid antigen version of the QFT-G test, which has
been replaced by the In-Tube version of the test (QFT-
GIT) in most countries worldwide. This makes comparisons
of our results with those from other studies diﬃcult as
most other studies have used QFT-GIT. Since Harada et
al. have shown that QFT-GIT has higher sensitivity than
QFT-G with the same high speciﬁcity [21], it could be
expected that the better performance would be obtained
than that obtained in this study. The relatively small number
of patients with conﬁrmed active TB limited any detailed
analysis of sensitivity and the small number of patients for
whom TST results were available limited comparison of test
performance.
5. Conclusion
In HIV-infected individuals, sensitivity and speciﬁcity of
the TST for the diagnosis of TB infection were poor under
the inﬂuence of BCG vaccination. In contrast, our data
suggested that QFT-G had high sensitivity and speciﬁcity in
HIV-infected populations with CD4+ Tc e l lc o u n tg r e a t e r
than 50/μL. However, neither test performed well in HIV-
positive patients with CD4+ T cell count less than 50/μL.
Therefore, care should be taken when interpreting negative
or indeterminate QFT-G results in HIV-infected patients
with CD4+ T cell count less than 50/μL. Further studies
in HIV-infected people are required to accumulate more
QFT-G performance data in active TB patients in developed
countries.
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